TroniWBergaminiL. Fisipatologia delle vie piramidali. In: Trattato di Medicina Fisica e Riabilitazione. Trattato di Medicina Fisica e riabilitazione, 445–452, 1985.
2.
LanceJ.W.. : The control of muscle tone, reflexes and movement. Neurology (NY)1980;30:1303–1313.
3.
CosgroveAPCorryISGrahamHK. Botulinum toxin in the management ofthe lower limb in cerebral palsy. Dev Med Child Neurol1994;36:386–96.
4.
DelwaidePJ. Contribution of human reflex studies to the understunding and management of Pyramidal Syndrome, in ShahaniTB. (ed.), Electromyography in CNS Disorders: Central EMG, Butterworth Publishers, pp 77–110. 1994.
5.
IlesJFRobertsRC. Presynaptic inhibition of monosynaptic reflexes in the lower limbs of subjects with upper motorneuron disease. J Neurol Neurosurg Psychiat, 1986;49:937–944.
6.
GailPLanceJWNeilsonPD. Differential effects on tonic and phasic reflex mechanisms produced by vibration of muscles in man. J. Neurol. Neurosurg. Psychiatry, 1966;29:1–11.
7.
BoydRNGrahamHK. Objective measurement of clinical findings in the use of botulinium toxin type A for the management of children with cerebral palsy. Eur J Neurol1999; 6 (Suppl. 4): S23–S35.
8.
GiorgiLBerzeroGFViolaE, Eziopatogenesi e fisiopatologia della spasticità. Riv Chir Riab Mano Arto Sup. 2000;38 (1):9–12.
9.
RicciardiL. Fisiopatologia del muscolo spastico. Riv Chir Riab Mano Arto Sup, 2000;38 (1):13–16.
10.
KomanLAMooneyJF. Botulinum toxin type A neuromuscular blockade in the treatment of lower limb spasticity in cerebral palsy: A randomised double-blind placebo controlled trial. J Pediatr Orthop2000;20:108–15.
11.
JeffersonRJ. Botulinum toxin in the management of cerebral palsy. Dev Med Child Neurol2004;46:491–499.
